|

SHR-1701 Clinical Trials

2 actively recruiting trials

No change since June 2026

Pipeline

Phase 2: 1

Top Sponsors

  • Nanjing Tianyinshan Hospital1
  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences1

Indications

  • Cancer2
  • Liver Disease1
  • Gastroesophageal Junction Adenocarcinoma1
  • Hepatocellular Carcinoma (HCC)1
  • Gastric Cancer (GC)1

Other2 trials

Chemoradiotherapy and SHR-1701 in Patients With Unresectable Gastric Cancer
Phase 2
Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma
N/A

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.